Health Care • Biotechnology: Pharmaceutical Preparations
$3.65 ▼ -0.03
(-0.81%)
MKT CAP: $303.7M • VOL: 709.6K
52W L $2 52W H $7
IRD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $14.2M | $11.0M | $19.0M |
| YoY Revenue Growth % | +29.1% | -42.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$38.6M | -$62.1M | -$10.6M |
| Operating Margin % | -80.0% | -80.0% | -55.5% |
| Net Income (GAAP) | -$49.6M | -$57.5M | -$10.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$35.3M | -$25.6M | -$1.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$35.3M | -$25.6M | -$1.1M |
| FCF Margin % | -80.0% | -80.0% | -5.8% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $45.1M | $30.3M | — |
| Total Debt (Short + Long Term) | $1.1M | $0 | — |
| Total Stockholders' Equity | $15.3M | $6.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IRD.